Nektar Therapeutics (NKTR) Releases Earnings Results, Beats Estimates By $0.13 EPS

Nektar Therapeutics (NASDAQ:NKTR) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.13, RTT News reports. Nektar Therapeutics had a net margin of 59.71% and a return on equity of 79.66%. During the same quarter in the prior year, the business posted ($0.21) earnings per share.

NKTR stock traded down $3.78 during mid-day trading on Friday, hitting $36.76. 91,766 shares of the company were exchanged, compared to its average volume of 1,836,665. The company has a quick ratio of 13.80, a current ratio of 13.93 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $6.93 billion, a PE ratio of -66.76 and a beta of 3.03. Nektar Therapeutics has a 1-year low of $29.22 and a 1-year high of $111.36.

A number of equities analysts have recently commented on the stock. Mizuho restated a “buy” rating and set a $81.00 price objective on shares of Nektar Therapeutics in a research note on Wednesday, January 23rd. ValuEngine upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th. HC Wainwright reiterated a “hold” rating and issued a $47.00 target price on shares of Nektar Therapeutics in a research note on Tuesday, February 19th. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 14th. Finally, BMO Capital Markets started coverage on shares of Nektar Therapeutics in a research note on Friday, February 22nd. They issued an “outperform” rating and a $75.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $79.45.

In other Nektar Therapeutics news, COO John Nicholson sold 63,000 shares of the firm’s stock in a transaction that occurred on Monday, January 28th. The shares were sold at an average price of $42.82, for a total transaction of $2,697,660.00. Following the completion of the sale, the chief operating officer now directly owns 237,477 shares in the company, valued at $10,168,765.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Jillian B. Thomsen sold 1,808 shares of the firm’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $42.39, for a total transaction of $76,641.12. The disclosure for this sale can be found here. Insiders have sold 241,824 shares of company stock valued at $10,249,993 over the last 90 days. Company insiders own 4.31% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Nektar Therapeutics (NKTR) Releases Earnings Results, Beats Estimates By $0.13 EPS” was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://transcriptdaily.com/2019/03/01/nektar-therapeutics-nktr-releases-earnings-results-beats-estimates-by-0-13-eps.html.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Read More: Calculate Your Return on Investment (ROI)

Earnings History for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply